ZA202001114B - Dynamic human heavy chain antibody libraries - Google Patents

Dynamic human heavy chain antibody libraries

Info

Publication number
ZA202001114B
ZA202001114B ZA2020/01114A ZA202001114A ZA202001114B ZA 202001114 B ZA202001114 B ZA 202001114B ZA 2020/01114 A ZA2020/01114 A ZA 2020/01114A ZA 202001114 A ZA202001114 A ZA 202001114A ZA 202001114 B ZA202001114 B ZA 202001114B
Authority
ZA
South Africa
Prior art keywords
heavy chain
antibody
libraries
chain antibody
human heavy
Prior art date
Application number
ZA2020/01114A
Other languages
English (en)
Inventor
Peizhi Luo Peter
Li Yan
Du Fangyong
Original Assignee
Adagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Inc filed Critical Adagene Inc
Publication of ZA202001114B publication Critical patent/ZA202001114B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/04—Methods of creating libraries, e.g. combinatorial synthesis using dynamic combinatorial chemistry techniques
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2020/01114A 2017-08-21 2020-02-21 Dynamic human heavy chain antibody libraries ZA202001114B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/098299 WO2019036842A1 (en) 2017-08-21 2017-08-21 DYNAMIC LIBRARIES OF HUMAN HEAVY CHAIN ANTIBODIES

Publications (1)

Publication Number Publication Date
ZA202001114B true ZA202001114B (en) 2024-06-26

Family

ID=65438261

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/01114A ZA202001114B (en) 2017-08-21 2020-02-21 Dynamic human heavy chain antibody libraries

Country Status (12)

Country Link
US (3) US11578426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3673101A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020537632A (cg-RX-API-DMAC7.html)
KR (2) KR102907590B1 (cg-RX-API-DMAC7.html)
CN (1) CN111279024B (cg-RX-API-DMAC7.html)
AU (1) AU2017428737B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003622A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072143A1 (cg-RX-API-DMAC7.html)
IL (1) IL272696B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202001551YA (cg-RX-API-DMAC7.html)
WO (1) WO2019036842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001114B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001549UA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human antibody light chain libraries
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
AU2017428737B2 (en) 2017-08-21 2024-02-15 Adagene Inc. Dynamic human heavy chain antibody libraries
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CN114835811B (zh) * 2019-12-24 2024-03-26 宝船生物医药科技(上海)有限公司 抗csf1r分子及其用途
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
EP4225786A2 (en) * 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2023193239A1 (en) * 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
KR20260026665A (ko) 2024-08-20 2026-02-27 엘지디스플레이 주식회사 표시 장치

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
DE60224720D1 (en) 2001-11-22 2008-03-06 Univ Keio Re
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス, インコーポレイテッド PDGFRβおよびVEGF−Aを阻害するための組成物および方法
MX381912B (es) * 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN105247050B (zh) 2013-03-14 2020-06-16 天演药业 用于文库构建、亲和力结合剂筛选和其表达的整合系统
CN103603057B (zh) 2013-07-03 2016-01-06 深圳大学 基于可感染病毒颗粒型抗体重链库/轻链库的抗体筛选和制备方法
WO2016062989A1 (en) * 2014-10-22 2016-04-28 Crescendo Biologics Limited Human vh domain scaffolds
EP4477269A3 (en) 2015-09-20 2025-03-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
AU2017428737B2 (en) 2017-08-21 2024-02-15 Adagene Inc. Dynamic human heavy chain antibody libraries
SG11202001549UA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human antibody light chain libraries

Also Published As

Publication number Publication date
JP2024178314A (ja) 2024-12-24
NZ761783A (en) 2025-11-28
IL272696B1 (en) 2024-09-01
SG11202001551YA (en) 2020-03-30
KR20240110891A (ko) 2024-07-16
JP7856719B2 (ja) 2026-05-11
JP2023025026A (ja) 2023-02-21
US11578426B2 (en) 2023-02-14
US12385162B2 (en) 2025-08-12
EP3673101A1 (en) 2020-07-01
AU2017428737B2 (en) 2024-02-15
US20200248336A1 (en) 2020-08-06
IL272696A (en) 2020-04-30
EP3673101A4 (en) 2021-03-24
CN111279024B (zh) 2024-07-19
JP2020537632A (ja) 2020-12-24
AU2017428737A8 (en) 2020-03-12
KR102907590B1 (ko) 2026-01-05
US20260146368A1 (en) 2026-05-28
US20240240358A1 (en) 2024-07-18
WO2019036842A1 (en) 2019-02-28
AU2017428737A1 (en) 2020-03-05
CN111279024A (zh) 2020-06-12
BR112020003622A2 (pt) 2020-09-01
IL272696B2 (en) 2025-01-01
KR20200038996A (ko) 2020-04-14
CA3072143A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
ZA202001112B (en) Dynamic human antibody light chain libraries
AU2017428737A8 (en) Dynamic human heavy chain antibody libraries
ZA202002338B (en) Novel bispecific polypeptide complexes
AU2018337142A8 (en) Novel bispecific CD3/CD19 polypeptide complexes
CO2020008940A2 (es) Anticuerpos de unión a gprc5d
ZA201807750B (en) Chimeric antigen receptors and methods of making
MX372821B (es) Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.
PY1829572A (es) Dominios de unión a antígeno humanizados y métodos de uso
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2018007206A (es) Anticuerpos biespecificos heterodimericos.
MY200602A (en) Antibodies against tim3 and uses thereof
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
IN2014DN08163A (cg-RX-API-DMAC7.html)
UY40672A (es) “ANTICUERPOS AISLADOS BIESPECÍFICOS GPRC5D x CD3 Y COMPOSICIONES QUÍMICAS QUE LOS CONTIENEN”
MX2022006230A (es) Anticuerpos contra cd3 y bcma, y proteinas de union biespecificas hechas a partir de estos.
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
PY1827107A (es) Anticuerpo monoclonal anti-pd-l1
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
JOP20230230A1 (ar) جسم مضاد ثلاثي النوعية يستهدف CD79b، وCD20، وCD3
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
WO2020247929A8 (en) High affinity anti-cd3 antibodies, and methods for their generation and use
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
CO2019010164A2 (es) Anticuerpos que se unen a steap-1
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
MX2020012589A (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.